Allogene Therapeutics (ALLO) Non Operating Income (2019 - 2025)
Historic Non Operating Income for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $3.5 million.
- Allogene Therapeutics' Non Operating Income fell 3612.48% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 9484.24%. This contributed to the annual value of $16.1 million for FY2024, which is 19000.28% up from last year.
- Latest data reveals that Allogene Therapeutics reported Non Operating Income of $3.5 million as of Q3 2025, which was down 3612.48% from $5.9 million recorded in Q2 2025.
- Allogene Therapeutics' Non Operating Income's 5-year high stood at $5.9 million during Q2 2025, with a 5-year trough of -$6.9 million in Q4 2023.
- In the last 5 years, Allogene Therapeutics' Non Operating Income had a median value of $511000.0 in 2021 and averaged $380736.8.
- Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 65122.41% in 2022, then soared by 30538.46% in 2024.
- Quarter analysis of 5 years shows Allogene Therapeutics' Non Operating Income stood at -$1.8 million in 2021, then plummeted by 101.27% to -$3.6 million in 2022, then crashed by 90.65% to -$6.9 million in 2023, then soared by 114.34% to $994000.0 in 2024, then skyrocketed by 252.21% to $3.5 million in 2025.
- Its Non Operating Income stands at $3.5 million for Q3 2025, versus $5.9 million for Q2 2025 and $5.5 million for Q1 2025.